Low molecular weight
protein tyrosine phosphatases (LMW-
PTPs) are an
enzyme family that plays a key role in cell proliferation control by dephosphorylating/inactivating both
tyrosine kinase receptors (such as PDGF,
insulin, and
ephrin receptors) and docking
proteins (such, as
beta-catenin) endowed with both adhesion and transcriptional activity. Besides being a frequent event in human
tumors, overexpression of LMW-PTP has been recently demonstrated to be sufficient to induce neoplastic transformation. We recently demonstrated that overexpression of LMW-PTP strongly potentiates the stability of cell-cell contacts at the adherens junction level, which powerfully suggests that LMW-PTP may also contribute to
cancer invasivity. Focusing on mechanisms by which LMW-PTP is involved in
cancer onset and progression, the emerging picture is that LMW-PTP strongly increases
fibronectin-mediated cell adhesion and mobility but, paradoxically, decreases cell proliferation. Nevertheless, LMW-PTP-transfected NIH3T3 fibroblasts engrafted in nude mice induce the onset of larger
fibrosarcomas, which are endowed with higher proliferation activity as compared to mock-transfected controls. Quite opposite effects have been obtained with engrafted fibroblasts transfected with a dominant-negative form of LMW-PTP. Notably, in
sarcoma extracts, LMW-PTP overexpression greatly influences the
ephrin A2 (EphA2) but not
PDGF receptor or
beta-catenin tyrosine phosphorylation. The high association of dephosphorylated EphA2 overexpression with most human
cancers and our observation that cell growth stimulation by LMW-PTP overexpression is restricted to the in vivo model, strongly suggest that LMW-PTP oncogenic potential is mediated by its EphA2
tyrosine dephosphorylating activity.